Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Vipoma 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Solid Tumors 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gastrinoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Breast Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

trametinib 1spartalizumab 1pembrolizumab 1motesanib diphosphate 1lenvatinib 1dabrafenib 1Sorafenib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid cancer, Hurthle cell × motesanib diphosphate × Clear all
NCT00121628 2013-10-09

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Amgen

Phase 2 Completed
184 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡